Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Allogeneic transplants via Blood/Marrow Transplant Program show better outcomes

For the fourth consecutive year, outcomes for patients receiving allogeneic transplants through the Blood and Marrow Transplant Program at Roswell Park Cancer Institute (RPCI) have been shown to be significantly better than would be expected among the patient population treated.

29 Jan 2014

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML). As a result, mutant IDH proteins have been proposed as attractive drug targets for this common form of adult leukemia.

29 Jan 2014

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE.

28 Jan 2014

Everolimus fails to boost advanced NSCLC response

Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.

28 Jan 2014

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced the FDA acceptance of its New Drug Application (NDA) for its lead product candidate, MPI-2505, a subcutaneous injectable methotrexate (MTX) in a ready-to-use injection device, for which the proposed indications are rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

28 Jan 2014

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections.

28 Jan 2014

Practicing yoga for atleast 3 months can reduce fatigue and inflammation in breast cancer survivors

Practicing yoga for as little as three months can reduce fatigue and lower inflammation in breast cancer survivors, according to new research.

27 Jan 2014

BRAF mutations rare in Japanese NSCLC patients

Research in a Japanese cohort of patients with non-small-cell lung cancer indicates that the frequency of BRAF mutations is low and their presence has limited prognostic significance.

27 Jan 2014

South Korean lung SCC genetic secrets revealed

Close examination of DNA taken from squamous cell carcinoma of the lung in South Korean patients has identified a gene fusion that may be targeted by current treatments, scientists say.

27 Jan 2014

DKFZ, AstraZeneca EORTC join Worldwide Innovative Network Consortium

The Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine is proud to announce that AstraZeneca, DKFZ and EORTC have joined the Consortium.

27 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

Music therapy interventions may provide essential psychosocial support to young patients with cancer

A new study has found that adolescents and young adults undergoing cancer treatment gain coping skills and resilience-related outcomes when they participate in a therapeutic music process that includes writing song lyrics and producing videos.

27 Jan 2014

LA BioMed's physician-researchers honored with America's Top Doctors for the year 2014

Forty-two of Los Angeles Biomedical Research Institute's (LA BioMed's) physician-researchers will be ranked among America's Top Doctors when it issues its 2014 publication later this year or they are listed among the Southern California Super Doctors for 2014 in the January edition of Los Angeles Magazine.

25 Jan 2014

Actavis signs agreement with Zhejiang Chiral to acquire Actavis Foshan, China

Actavis plc today announced that it has signed and completed an agreement for Zhejiang Chiral Medicine Chemicals Co., Ltd to acquire Actavis' interest in Actavis (Foshan) Pharmaceuticals Co., Ltd., an Actavis subsidiary based in Foshan, China.

25 Jan 2014

Large-scale analysis of over 20 tumor types increases catalog of cancer genes by 25%

A landmark study across many cancer types reveals that the universe of cancer mutations is much bigger than previously thought. By analyzing the genomes of thousands of patients' tumors, a Broad Institute-led research team has discovered many new cancer genes - expanding the list of known genes tied to these cancers by 25 percent. Moreover, the study shows that many key cancer genes still remain to be discovered.

25 Jan 2014

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma.

25 Jan 2014

BIDMC aims to improve family engagement and reduce overall risk of harm in ICU

Beth Israel Deaconess Medical Center is embarking on a new phase of its mission to eliminate preventable harm, using information technology and system science together with patient and family engagement to head off harm before it happens.

25 Jan 2014

Oncology News and Research

Further Reading

Allogeneic transplants via Blood/Marrow Transplant Program show better outcomes

Transgenic mouse model validates mutant IDH2 protein as candidate for targeted anticancer therapies

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Everolimus fails to boost advanced NSCLC response

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

Practicing yoga for atleast 3 months can reduce fatigue and inflammation in breast cancer survivors

BRAF mutations rare in Japanese NSCLC patients

South Korean lung SCC genetic secrets revealed

DKFZ, AstraZeneca EORTC join Worldwide Innovative Network Consortium

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Music therapy interventions may provide essential psychosocial support to young patients with cancer

LA BioMed's physician-researchers honored with America's Top Doctors for the year 2014

Actavis signs agreement with Zhejiang Chiral to acquire Actavis Foshan, China

Large-scale analysis of over 20 tumor types increases catalog of cancer genes by 25%

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

BIDMC aims to improve family engagement and reduce overall risk of harm in ICU

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News